39 0
Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR.
Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at


Many Thanks.

ZH 繁體中文
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
AR العربية
HE עברית
首頁 股票篩選器 外匯篩選器 加密貨幣篩選器 全球財經日曆 如何運作 圖表功能 網站規則 版主 網站 & 經紀商解決方案 小工具 圖表庫 功能請求 部落格 & 新聞 常見問題 幫助 & 維基 推特
個人資料 個人資料設定 帳戶和帳單 我的客服工單 聯絡客服 發表的想法 粉絲 正在關注 私人訊息 在線聊天 登出